NCT04348149 is a NA clinical trial of Lindera obtusiloba extract in Non Small Cell Lung Cancer, sponsored by Jun-Yong Choi.

Who is sponsoring NCT04348149?

NCT04348149 is sponsored by Jun-Yong Choi.

What drugs are being tested in NCT04348149?

Interventions in NCT04348149: Lindera obtusiloba extract.

What condition does NCT04348149 study?

NCT04348149 studies Non Small Cell Lung Cancer.

Is NCT04348149 still recruiting?

NCT04348149 is currently status unknown. Last updated 16 April 2020.

Last reviewed 2020-04-16 · How we verify

NCT04348149

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lindera Obtusiloba for Non-small Cell Lung Cancer

Status unknown NA Last updated 16 April 2020

What this trial tests

NA trial testing Lindera obtusiloba extract in Non Small Cell Lung Cancer in 20 participants. Status unknown.

Timeline

28 December 2018

Primary endpoint
27 December 2020

27 December 2020

Quick facts

Lead sponsor	Jun-Yong Choi
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	20
Start date	28 December 2018
Primary completion	27 December 2020
Estimated completion	27 December 2020
Sites	1 location across South Korea

Drugs / interventions tested

Lindera obtusiloba extract

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →

Sponsor

Jun-Yong Choi

Who can join

20 and older, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized, open labelled, non-treatment-controlled study evaluates the safety and efficacy of Lindera obtusiloba, a dietary food, on quality of life of non-small cell lung cancer patients who are receiving PD-1 or PD-L1 inhibitors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Foods may modify responsiveness to cancer immune checkpoint blockers by altering both the gut microbiota and activation of estrogen receptors in immune cells.
Hilakivi-Clarke L, Verma V, McDermott M, Koak P, et al · · 2022 · cited 1× · PMID 41852822 · DOI 10.3389/frmbi.2022.1049688

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04348149 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jun-Yong Choi
Last refreshed: 16 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04348149.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing